Background: Burkholderia pseudomallei is the causative agent of melioidosis, a disease endemic throughout the tropics.
Introduction
Burkholderia pseudomallei, an environmental Gram-negative bacterium, is the causative agent of melioidosis. 1 There are an estimated 165 000 human cases with 89 000 deaths annually worldwide. 2 It is thought to be endemic in northern Thailand; however, only sporadic reports have emerged to date. 2 Transmission occurs through percutaneous inoculation, inhalation or aspiration. 1 Risk factors include diabetes mellitus, alcoholism, chronic lung disease and chronic kidney disease. 3 Clinical misdiagnosis of melioidosis regularly occurs due to its protean manifestations, ranging from mild fever to fatal septic shock. 1, 3 Diagnosis is typically made by culture of clinical specimens and identification of B. pseudomallei using conventional microbiological techniques including Gram stain, oxidase test, biochemical tests and antibiotic susceptibility tests. 4, 5 Additionally, latex agglutination, identification kits (e.g. API20NE), matrix-assisted light desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) and molecular tests can provide further confirmation. 5 However, laboratory misidentification can occur due to lack of awareness, inadequate quality assurance or limited resources. Treatment involves an intensive phase with intravenous (IV) ceftazidime or meropenem for 10-14 d followed by an eradication phase of 3-6 months with oral co-trimoxazole or co-amoxiclav. 1 Here we report five culture-confirmed cases whose B. pseudomallei had been misidentified as Acinetobacter spp.
Materials and methods
A study of reported Acinetobacter spp. bacteraemia was conducted at Chiang Rai provincial hospital, in northern Thailand, from December 2014 to December 2015. Clinical blood culture isolates originally identified as Acinetobacter spp. by the local hospital laboratory using conventional microbiological techniques were prospectively collected. These isolates were subcultured and Table 1 and details of the blood culture results for each patient in Table 2 . Admission blood cultures were reported within 22-40 h of collection as Acinetobacter spp., while antibiotic susceptibility results were reported 16-24 h later. All had underlying disease associated with an increased risk of melioidosis. Four cases had severe disease, were elderly, developed multi-organ failure and died (patients 1, 2, 4 and 5). The initial empirical treatment in these patients included IV ceftriaxone or IV piperacillin/tazobactam with additional antibiotics in some cases (e.g. amikacin, roxithromycin, azithromycin, doxycycline and vancomycin). Only two of the four severe cases received melioidosis-appropriate antibiotics-IV meropenem in both cases-with delays of 1 and 4 d from admission (patients 2 and 5, respectively). The other two severe cases died within 48 h of admission (patients 1 and 4). The patient who survived was younger, had mild disease, had previously been diagnosed with genitourinary tract melioidosis and was already on appropriate treatment (IV ceftazidime), which was continued despite the misleading admission blood culture result (patient 4).
In this report we confirm the presence of melioidosis in northern Thailand and demonstrate that laboratory misidentification of Acinetobacter spp. as B. pseudomallei or other bacteria remains commonplace. The predicted mortality from melioidosis R. C. Greer et al.
in Thailand is 37.5%, while 4/5 (80%) patients in this study died. 2 This confirms the high mortality associated with melioidosis, especially when compounded by misdiagnosis and delays in initiating effective treatment. However, earlier initiation of appropriate antibiotics alone, without timely and adequate intensive care support, may not improve the outcome in severe disease. 3 Empirical ceftriaxone and piperacillin/tazobactam were used: ceftriaxone has moderate in vitro activity against B. pseudomallei, while susceptibility to piperacillin/tazobactam has also been shown. 6, 7 Despite these findings, ceftriaxone is less effective than ceftazidime and clinical experience with piperacillin/tazobactam is limited. 8 Correct identification on admission blood culture might have improved the outcome in one patient where appropriate treatment was delayed for 4 d. Even in endemic areas, microbiology laboratories can struggle to identify B. pseudomallei. Training and introduction of a simple laboratory algorithm have been shown to be effective in diagnosing melioidosis in Vietnam. 4 During the study period, nine other patients had melioidosis diagnosed from positive blood cultures, demonstrating that local laboratory staff are capable of identifying B. pseudomallei, albeit inconsistently. In addition, this study shows that data from routine laboratory-based surveillance systems, even in countries like Thailand with relatively well-developed health care facilities, should be treated with caution.
Conclusions
Making the correct diagnosis is vital to patient outcome and fundamental to any effective surveillance and antimicrobial stewardship programmes. The diagnosis and management of melioidosis remain suboptimal in many endemic regions. The misidentification of B. pseudomallei and other bacteria demonstrated in this report highlights the need to prioritize and strengthen laboratory capacity and quality. Following discussions with local stakeholders, plans are under way to provide additional training, improve quality assurance and introduce consistent use of new diagnostics (e.g., latex agglutination test, API20NE and VITEK) within the microbiology laboratory. Efforts to increase the clinical awareness of melioidosis, including the importance of effective and timely treatment in at-risk patients, are also required.
